Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Thoracic 1Lymphoid 1

Conditions

Prostatic Neoplasms 3Recurrence 1Metastatic Castration-Resistant Prostate Cancer 1Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 98Specimen Handling 79pembrolizumab 75enzalutamide 63Nivolumab 59Gemcitabine 54Docetaxel 50apalutamide 42Radiosurgery 41Abiraterone Acetate 40Androgen Antagonists 39Prednisone 38Biopsy 37darolutamide 35Cisplatin 35cabozantinib 31Radiotherapy 31Carboplatin 28Pluvicto 27abiraterone 26enfortumab vedotin 24Ipilimumab 24Radiation 23durvalumab 22atezolizumab 22Leuprolide 20olaparib 18X-Rays 18Standard of Care 18avelumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
PF06821497 × Genitourinary × 90 days × Clear all
NCT06629779 2026-06-05

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Pfizer

Phase 3 Recruiting
900 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT07028853 2026-06-05

MEVPRO-3

Pfizer

Phase 3 Recruiting
1,000 enrolled
Genitourinary

Prostatic Neoplasms

NCT07592910 2026-05-18

MOMENT

Prostate Cancer Clinical Trials Consortium

Phase 2 Not yet recruiting
60 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT06551324 2026-05-05

MEVPRO-1

Pfizer

Phase 3 Active not recruiting
600 enrolled
Genitourinary

Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡